The rising prevalence in GLP-1 agonists for diabetes has sparked a debate about delivery routes : skin-applied devices versus pills . Usually , GLP-1 treatments were exclusively available in oral form, but https://gretakvnr525372.bloguerosa.com/39649888/glp-1-transdermal-delivery-systems-vs-pills-is-suitable-for-the-patient